Autores
Peter J Campbell, Linda M Scott, Georgina Buck, Keith Wheatley, Clare L East, Joanne T Marsden, Audrey Duffy, Elaine M Boyd, Anthony J Bench, Mike A Scott, George S Vassiliou, Donald W Milligan, Steve R Smith, Wendy N Erber, David Bareford, Bridget S Wilkins, John T Reilly, Claire N Harrison, Anthony R Green
Fecha de publicación
2005/12/3
Revista
The Lancet
Volumen
366
Número
9501
Páginas
1945-1953
Editor
Elsevier
Descripción
Background
An acquired V617F mutation in JAK2 occurs in most patients with polycythaemia vera, but is seen in only half those with essential thrombocythaemia and idiopathic myelofibrosis. We aimed to assess whether patients with the mutation are biologically distinct from those without, and why the same mutation is associated with different disease phenotypes.
Methods
Two sensitive PCR-based methods were used to assess the JAK2 mutation status of 806 patients with essential thrombocythaemia, including 776 from the Medical Research Council's Primary Thrombocythaemia trial (MRC PT-1) and two other prospective studies. Laboratory and clinical features, response to treatment, and clinical events were compared for V617F-positive and V617F-negative patients with essential thrombocythaemia.
Findings
Mutation-positive patients had multiple features resembling polycythaemia vera, with significantly …
Citas totales
Artículos de Google Académico
PJ Campbell, LM Scott, G Buck, K Wheatley, CL East… - The Lancet, 2005